ZyVersa Therapeutics Inc.

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes products for renal and inflammatory diseases. Its drug development platforms include Cholesterol Efflux Mediator VAR 200, an injectable drug in Phase 2a clinical trials for renal indications such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney diseases. It also develops Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has license agreements with L&F Research LLC and InflamaCORE, LLC, and was founded in 2014 in Weston, Florida.